CSIMarket


Acro Biomedical Co Ltd   (ACBM)
Other Ticker:  
 
    Sector  Services    Industry Movies and Entertainment
   Industry Movies and Entertainment
   Sector  Services


 

Acro Biomedical Co Ltd

ACBM's Financial Statements and Analysis



Acro Biomedical Co Ltd reported in the second quarter of 2023 net loss per share of $-0.05 compare to earnings per share of $0.00 in the same quarter a year ago and improved compare to net loss per share of $-0.07 realized in previous quarter.


second quarter of 2023
Earnings Per Share Revenues
$ -0.05 $  0 Mill
$-0.05     Unch.    



Acro Biomedical Co Ltd 's Revenue fell by 0 % in second quarter of 2023 (Jun 30 2023) year on year, to $0 million and declined by sequentially.


Acro Biomedical Co Ltd is Expected to report next financial results on July 20, 2024.

More on ACBM's Income Statement



Acro Biomedical Co Ltd 's in thesecond quarter of 2023 recorded net loss of $-3.195 million, an improvement compare to net loss of $-3.997 million in II. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-4.004 million realized in previous quarter.

More on ACBM's Growth

Acro Biomedical Co Ltd Inventories
ACBM's Cash flow In the second quarter of 2023 company's net cash flow was $0 million


Acro Biomedical Co Ltd does not pay out common stock dividend.

In trailing twelve-month period Acro Biomedical Co Ltd payed $ 0.00 cash per share, on a free-cash flow basis .

Book value fell by -17.34 % sequentially to $0.01 per share, -0.64% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.01 per share from $ 0.01.

Company repurchased 0.00 million shares or 0.00 % in Jun 30 2023.


More on ACBM's Dividends

 Market Capitalization (Millions) 123
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Acro Biomedical Co Ltd does not pay out common stock dividend.

In trailing twelve-month period Acro Biomedical Co Ltd had negative $ 0.00 cash flow per share, on a free-cash flow basis .

Book value fell by -17.34 % sequentially to $0.01 per share, -0.64% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.01 per share from $ 0.01.

Company repurchased 0.00 million shares or 0.00 % in Jun 30 2023.


More on ACBM's Balance Sheets

 Market Capitalization (Millions) 123
 Shares Outstanding (Millions) 60
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Acro Biomedical Co Ltd Earnings

Acro Biomedical Co Ltd Delivers Positive Financial Results, Highlighting Significant Improvement in Operating Loss


Introduction
Acro Biomedical Co Ltd, a well-known Movies and Entertainment company, has recently announced its financial results for the April to June 2023 reporting season. The company's top-line adjustments were not initially considered by investors; however, what caught their attention was the significant improvement in the operating loss. This article aims to examine the positive developments and the impact they may have on the company's future prospects.
Operating Loss and Market Observers Affirmation
During the reported period of April to June 2023, Acro Biomedical Co Ltd experienced an operating loss of $3.1947 million. Although this may seem like negative news at first glance, it is ...

ACBM Holds Steady: Revenues Mirror Last Fiscal Year Despite Mounting Challenges



Acro Biomedical Co Ltd, a company operating in an undisclosed industry, recently released its financial results for the most recent fiscal period. The results indicate a concerning increase in loss per share compared to the previous year, a decline in revenue, and a larger net shortfall. This article aims to interpret these financial figures and explore the potential impact they may have on Acro Biomedical Co Ltd's future.
1. Increased Shortfall per Share:
Acro Biomedical Co Ltd experienced a significant increase in shortfall per share, standing at $-0.07 compared to $0.00 from the previous year. This indicates that the company's expenses have exceeded its revenue, which could raise concern...


Date modified: 2023-08-16T09:32:13+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com